Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$21.53 - $26.8 $1.72 Million - $2.14 Million
-80,000 Reduced 20.78%
305,000 $7.06 Million
Q4 2022

Feb 14, 2023

SELL
$18.63 - $27.35 $2.61 Million - $3.83 Million
-140,000 Reduced 26.67%
385,000 $10.1 Million
Q3 2022

Nov 14, 2022

SELL
$17.51 - $23.37 $1.58 Million - $2.1 Million
-90,000 Reduced 14.63%
525,000 $10.3 Million
Q2 2022

Aug 15, 2022

BUY
$12.59 - $18.8 $881,300 - $1.32 Million
70,000 Added 12.84%
615,000 $10.8 Million
Q4 2021

Feb 14, 2022

BUY
$10.69 - $16.83 $855,200 - $1.35 Million
80,000 Added 17.2%
545,000 $8.89 Million
Q3 2021

Nov 15, 2021

BUY
$11.5 - $14.86 $556,979 - $719,714
48,433 Added 11.63%
465,000 $5.26 Million
Q2 2021

Aug 13, 2021

BUY
$13.6 - $18.98 $2.87 Million - $4 Million
210,768 Added 102.41%
416,567 $5.88 Million
Q4 2020

Feb 16, 2021

BUY
$11.9 - $20.91 $2.45 Million - $4.3 Million
205,799 New
205,799 $3.26 Million

Others Institutions Holding KDNY

About CHINOOK THERAPEUTICS, INC.


  • Ticker KDNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,896,300
  • Description
  • Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...
More about KDNY
Track This Portfolio

Track Altium Capital Management LP Portfolio

Follow Altium Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Altium Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Altium Capital Management LP with notifications on news.